The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co is capitalizing on trends prevalent in both the biopharma industry and its customer base to build one of the fastest- growing specialty pharma franchises. Results for 2012 confirm the strategy has worked to date.
You may also be interested in...
The Medicines Co. Enters PCSK9 Race With Alnylam Deal
The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.